Comparison of naïve and central memory derived CD8+ effector cell engraftment fitness and function following adoptive transfer

OncoImmunology

Volumn 5, Issue 1, 2016, Pages

  Wang, Xiuli ^a   Wong, ChingLam W ^a   Urak, Ryan ^a   Taus, Ellie ^a   Aguilar, Brenda ^a   Chang, Wen Chung ^a   Mardiros, Armen ^a   Budde, Lihua E ^a   Brown, Christine E ^a   Berger, Carolina ^b,c   Forman, Stephen J ^a   Jensen, Michael C ^b,c,d  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

adoptive therapy; Antitumor activity; central memory T cell derived CTLs; engraftment fitness; na ve T cell derived CTLs

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; GENOMIC DNA; INTERLEUKIN 15;

ADOPTIVE TRANSFER; AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; BIOLUMINESCENCE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL ISOLATION; CELL SURVIVAL; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; EFFECTOR CELL; ENGRAFTMENT; FITNESS; FLOW CYTOMETRY; GENE EXPRESSION; GENE FREQUENCY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOPHENOTYPING; IMMUNOREACTIVITY; LYMPHOBLASTOID CELL LINE; MEMORY T LYMPHOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUALITY CONTROL; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEM CELL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR CELL; XENOGRAFT;

EID: 85014749742     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1072671     Document Type: Article

References (46)

1. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013; 368:1509-18; PMID:23527958; http://dx.doi.org/10.1056/NEJMoa1215134
2. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3:95ra73; PMID:21832238; http://dx.doi.org/10.1126/scitranslmed.3002842
3. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013; 5:177ra38; PMID:23515080; http://dx.doi.org/10.1126/scitranslmed.3005930
4. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012; 119:2709-20; PMID:22160384; http://dx.doi.org/10.1182/blood-2011-10-384388
5. + T cells in immunodeficient mice. Blood 2011; 117:1888-98; PMID:21123821; http://dx.doi.org/10.1182/blood-2010-10-310599
6. + T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 2008; 118:294-305; PMID:18060041; http://dx.doi.org/10.1172/JCI32103
7. Graef P, Buchholz VR, Stemberger C, Flossdorf M, Henkel L, Schiemann M, Drexler I, Hofer T, Riddell SR, Busch DH. Serial transfer of single-cell-derived immunocompetence reveals stemness of CD8(+) central memory T cells. Immunity 2014; 41:116-26; PMID:25035956; http://dx.doi.org/10.1016/j.immuni.2014.05.018
8. Gattinoni L. Memory T cells officially join the stem cell club. Immunity 2014; 41:7-9; PMID:25035947; http://dx.doi.org/10.1016/j.immuni.2014.07.003
9. Thomas ML, Lefrancois L. Differential expression of the leucocyte-common antigen family. Immunol Today 1988; 9:320-6; PMID:2978372; http://dx.doi.org/10.1016/0167-5699(88)91326-6
10. Terry LA, Brown MH, Beverley PC. The monoclonal antibody, UCHL1, recognizes a 180,000 MW component of the human leucocyte-common antigen, CD45. Immunology 1988; 64:331-6; PMID:2455685
11. + T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood 2011; 117:808-14; PMID:20971955; http://dx.doi.org/10.1182/blood-2010-05-286286
12. Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, Almeida JR, Gostick E, Yu Z, Carpenito C et al. A human memory T cell subset with stem cell-like properties. Nat Med 2011; 17:1290-7; PMID:21926977; http://dx.doi.org/10.1038/nm.2446
13. + T cell subsets in HIV-infected children. J Clin Invest 1995; 95:2054-60; PMID:7738172; http://dx.doi.org/10.1172/JCI117891
14. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401:708-12; PMID:10537110; http://dx.doi.org/10.1038/44385
15. Chattopadhyay PK, Betts MR, Price DA, Gostick E, Horton H, Roederer M, De Rosa SC. The cytolytic enzymes granyzme A, granzyme B, and perforin: expression patterns, cell distribution, and their relationship to cell maturity and bright CD57 expression. J Leukoc Biol 2009; 85:88-97; PMID:18820174; http://dx.doi.org/10.1189/jlb.0208107
16. + lymphocyte apoptosis, chronic disease, and immune regulation. Front Biosci (Landmark edition) 2009; 14:3771-81; PMID:19273309; http://dx.doi.org/10.2741/3487
17. Crossland KD, Lee VK, Chen W, Riddell SR, Greenberg PD, Cheever MA. T cells from tumor-immune mice nonspecifically expanded in vitro with anti-CD3 plus IL-2 retain specific function in vitro and can eradicate disseminated leukemia in vivo. J Immunol 1991; 146:4414-20; PMID:1674958
18. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992; 257:238-41; PMID:1352912; http://dx.doi.org/10.1126/science.1352912
19. Till BG, Jensen MC, Wang J, Chen EY, Wood BL, Greisman HA, Qian X, James SE, Raubitschek A, Forman SJ et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 2008; 112:2261-71; PMID:18509084; http://dx.doi.org/10.1182/blood-2007-12-128843
20. Cieri N, Camisa B, Cocchiarella F, Forcato M, Oliveira G, Provasi E, Bondanza A, Bordignon C, Peccatori J, Ciceri F et al. IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood 2013; 121:573-84; PMID:23160470; http://dx.doi.org/10.1182/blood-2012-05-431718
21. Jain J, Nalefski EA, McCaffrey PG, Johnson RS, Spiegelman BM, Papaioannou V, Rao A. Normal peripheral T-cell function in c-Fos-deficient mice. Mol Cell Biol 1994; 14:1566-74; PMID:8114694; http://dx.doi.org/10.1128/MCB.14.3.1566
22. Ochi Y, Koizumi T, Kobayashi S, Phuchareon J, Hatano M, Takada M, Tomita Y, Tokuhisa T. Analysis of IL-2 gene regulation in c-fos transgenic mice. Evidence for an enhancement of IL-2 expression in splenic T cells stimulated via TCR/CD3 complex. J Immunol 1994; 153:3485-90; PMID:7930571
23. Yaseen NR, Park J, Kerppola T, Curran T, Sharma S. A central role for Fos in human B- and T-cell NFAT (nuclear factor of activated T cells): an acidic region is required for in vitro assembly. Mol Cell Biol 1994; 14:6886-95; PMID:7935406; http://dx.doi.org/10.1128/MCB.14.10.6886
24. Sun J, Dotti G, Huye LE, Foster AE, Savoldo B, Gramatges MM, Spencer DM, Rooney CM. T cells expressing constitutively active Akt resist multiple tumor-associated inhibitory mechanisms. Mol Ther 2010; 18:2006-17; PMID:20842106; http://dx.doi.org/10.1038/mt.2010.185
25. + T cells. Proc Natl Acad Sci U S A 1999; 96:2976-81; PMID:10077622; http://dx.doi.org/10.1073/pnas.96.6.2976
26. + T cells show increased proliferative responses and IFN-gamma production following antigenic challenge in vitro. Int Immunol 1999; 11:699-706; PMID:10330275; http://dx.doi.org/10.1093/intimm/11.5.699
27. + T cell pool. J Immunol 2010; 184:35-44; PMID:19949092; http://dx.doi.org/10.4049/jimmunol.0803355
28. + T cells. J Immunol 2008; 180:4391-401; PMID:18354159; http://dx.doi.org/10.4049/jimmunol.180.7.4391
29. + T cells in ex vivo generated, antileukemia human cytotoxic T lymphocyte lines. J Immunother 2008; 31:385-93; PMID:18391757; http://dx.doi.org/10.1097/CJI.0b013e31816b1092
30. Wang X, Chang WC, Wong CW, Colcher D, Sherman M, Ostberg JR, Forman SJ, Riddell SR, Jensen MC. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 2011; 118:1255-63; PMID:21653320; http://dx.doi.org/10.1182/blood-2011-02-337360
31. Jonnalagadda M, Mardiros A, Urak R, Wang X, Hoffman LJ, Bernanke A, Chang WC, Bretzlaff W, Starr R, Priceman S et al. Chimeric antigen receptors with mutated IgG4 Fc spacer avoid Fc receptor binding and improve T cell persistence and anti-tumor efficacy. Mol Ther 2014; 23:757-68; PMID:25366031; http://dx.doi.org/10.1038/mt.2014.208
32. Hudecek M, Sommermeyer D, Kosasih PL, Silva-Benedict A, Liu L, Rader C, Jensen MC, Riddell SR. The non-signaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res 2014; 3:125-35; PMID:25212991; http://dx.doi.org/10.1158/2326-6066.CIR-14-0127
33. Berger C, Turtle CJ, Jensen MC, Riddell SR. Adoptive transfer of virus-specific and tumor-specific T cell immunity. Curr Opin Immunol 2009; 21:224-32; PMID:19304470; http://dx.doi.org/10.1016/j.coi.2009.02.010
34. + T cells. J Clin Invest 2005; 115:1616-26; PMID:15931392; http://dx.doi.org/10.1172/JCI24480
35. Wang A, Chandran S, Shah SA, Chiu Y, Paria BC, Aghamolla T, Alvarez-Downing MM, Lee CC, Singh S, Li T et al. The stoichiometric production of IL-2 and IFN-gamma mRNA defines memory T cells that can self-renew after adoptive transfer in humans. Sci Transl Med 2012; 4:149ra20; PMID:22932225; http://dx.doi.org/10.1126/scitranslmed.3004306
36. Sparrow RL, Komodromou H, Tippett E, Georgakopoulos T, Xu W. Apoptotic lymphocytes and CD34+ cells in cryopreserved cord blood detected by the fluorescent vital dye SYTO 16 and correlation with loss of L-selectin (CD62L) expression. Bone Marrow Transplant 2006; 38:61-7; PMID:16788684; http://dx.doi.org/10.1038/sj.bmt.1705405
37. Berard M, Tough DF. Qualitative differences between naive and memory T cells. Immunology 2002; 106:127-38; PMID:12047742; http://dx.doi.org/10.1046/j.1365-2567.2002.01447.x
38. Boesteanu AC, Katsikis PD. Memory T cells need CD28 costimulation to remember. Semin Immunol 2009; 21:69-77; PMID:19268606; http://dx.doi.org/10.1016/j.smim.2009.02.005
39. Lugli E, Dominguez MH, Gattinoni L, Chattopadhyay PK, Bolton DL, Song K, Klatt NR, Brenchley JM, Vaccari M, Gostick E et al. Superior T memory stem cell persistence supports long-lived T cell memory. J Clin Invest 2013; 123:594-9; PMID:23281401; http://dx.doi.org/10.1172/JCI66327
40. + central memory T cells manufactured at clinical scale. J Immunother 2012; 35:689-701; PMID:23090078; http://dx.doi.org/10.1097/CJI.0b013e318270dec7
41. Pelloquin F, Lamelin JP, Lenoir GM. Human B lymphocytes immortalization by Epstein-Barr virus in the presence of cyclosporin A. In Vitro Cell Dev Biol 1986; 22:689-94; PMID:3023278; http://dx.doi.org/10.1007/BF02621085
42. Donnelly ML, Hughes LE, Luke G, Mendoza H, ten Dam E, Gani D, Ryan MD. The ‘cleavage’ activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring ‘2A-like’ sequences. J Gen Virol 2001; 82:1027-41; PMID:11297677; http://dx.doi.org/10.1099/0022-1317-82-5-1027
43. Szymczak AL, Workman CJ, Wang Y, Vignali KM, Dilioglou S, Vanin EF, Vignali DA. Correction of multi-gene deficiency in vivo using a single ‘self-cleaving’ 2A peptide-based retroviral vector. Nat Biotechnol 2004; 22:589-94; PMID:15064769; http://dx.doi.org/10.1038/nbt957
44. Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N, Smith DD, Forman SJ, Jensen MC, Cooper LJ. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res 2006; 66:10995-1004; PMID:17108138; http://dx.doi.org/10.1158/0008-5472.CAN-06-0160
45. Stastny MJ, Brown CE, Ruel C, Jensen MC. Medulloblastomas expressing IL13Ralpha2 are targets for IL13-zetakine+ cytolytic T cells. J Pediatr Hematol Oncol 2007; 29:669-77; PMID:17921847; http://dx.doi.org/10.1097/MPH.0b013e3181468c68
46. + T cell subsets. J Immunol 2005; 175:5895-903; PMID:16237082; http://dx.doi.org/10.4049/jimmunol.175.9.5895